lartesertib (M4076)

P2, N=60, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting

P2, N=60, Not yet recruiting, EMD Serono Research & Development Institute, Inc.

P1, N=72, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Dec 2023 --> May 2026 | Trial primary completion date: Dec 2023 --> Mar 2026

P1, N=30, Completed, EMD Serono Research & Development Institute, Inc. | Active, not recruiting --> Completed

In cancer cells with functional ATM and p53 signaling, selective suppression of ATR catalytic activity by M6620 induced G1-phase arrest to prevent S-phase entry with unrepaired DSBs. The selective ATM inhibitors, M3541 and M4076, suppressed both ATM-dependent cell-cycle checkpoints, and DSB repair lowered the p53 protective barrier and extended the life of ATR inhibitor-induced DSBs...ATM inhibitor synergistically potentiated the ATR inhibitor efficacy in cancer cells in vitro and increased ATR inhibitor efficacy in vivo at doses that did not show overt toxicities. Further, a combination study in 26 patient-derived xenograft models of triple negative breast cancer with the newer generation ATR inhibitor M4344 and ATM inhibitor M4076 demonstrated substantial improvement in efficacy and survival compared to single-agent M4344, suggesting a novel and potentially broad combination approach to cancer therapy.

P1, N=30, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting

P1, N=30, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2022 --> May 2023

P1, N=30, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting

P1, N=30, Not yet recruiting, EMD Serono Research & Development Institute, Inc.